2. Search Result
Search Result
Results for "

proteasome+inhibitor

" in MedChemExpress (MCE) Product Catalog:

88

Inhibitors & Agonists

2

Fluorescent Dyes

2

Biochemical Assay Reagents

11

Peptides

14

Natural
Products

4

Isotope-Labeled Compounds

2

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10227
    Bortezomib
    Maximum Cited Publications
    248 Publications Verification

    PS-341; LDP-341; NSC 681239

    		 Proteasome NF-κB Apoptosis Autophagy TREM receptor Cancer
    Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM) . Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) .
    Bortezomib
  • HY-10455
    Carfilzomib
    60+ Cited Publications

    PR-171

    		 Proteasome Autophagy Apoptosis Cancer
    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells.
    Carfilzomib
  • HY-10453
    Ixazomib
    20+ Cited Publications

    MLN2238

    		 Proteasome Autophagy Cancer
    Ixazomib (MLN2238) is a selective, potent, and reversible proteasome inhibitor, which inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with an IC50 of 3.4 nM (Ki of 0.93 nM).
    Ixazomib
  • HY-13067
    Celastrol
    Maximum Cited Publications
    61 Publications Verification

    Tripterine; Tripterin

    		 Proteasome Autophagy Mitophagy Apoptosis Endogenous Metabolite Antibiotic Bacterial Nuclear Hormone Receptor 4A/NR4A Infection Inflammation/Immunology Cancer
    Celastrol (Tripterine;Tripterin) is a proteasome inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. In addition, Celastrol is also an antibiotic with potent antimicrobial activity against standard and clinical methicillin-resistant Staphylococcus aureus (MRSA) strains, inducing oxidative stress and inhibiting DNA synthesis by binding to P5CDH .
    Celastrol
  • HY-16594
    Lactacystin
    5+ Cited Publications

    		 Proteasome Cathepsin Apoptosis Cardiovascular Disease Infection Neurological Disease Cancer
    Lactacystin is a potent, orally active, irreversible, cell-permeable, selective 20S proteasome inhibitor (IC50 = 4.8 μM). Lactacystin also inhibits the lysosomal enzyme cathepsin A. Lactacystin inhibits cell growth and induces apoptosisand cell cycle arrest, and has antiviral and antioxidative activity. Lactacystin induces neurite outgrowth and hypertension. Lactacystin has the potential for the research of cancer, Neurological Disease, hypertension and Malaria, and so on [2] [6] .
    Lactacystin
  • HY-13821
    Epoxomicin
    20+ Cited Publications

    BU-4061T

    		 Proteasome Apoptosis Inflammation/Immunology Cancer
    Epoxomicin (BU-4061T) is an epoxyketone-containing natural product and a potent, selective and irreversible proteasome inhibitor. Epoxomicin covalently binds to the LMP7, X, MECL1, and Z catalytic subunits of the proteasome and potently inhibits primarily the chymotrypsin-like activity. Epoxomicin can cross the blood-brain barrier. Epoxomicin has strongly antitumor and anti-inflammatory activity .
    Epoxomicin
  • HY-13259C
    (R)-MG-132
    15+ Cited Publications

    (S,R,S)-(-)-MG-132; Z-Leu-D-Leu-Leu-al

    		 Proteasome Cancer
    (R)-MG-132 ((S,R,S)-(-)-MG-132) is the enantiomer of MG-132. (R)-MG-132 is a proteasome inhibitor with weaker cell cytotoxicity than MG-132 .
    (R)-MG-132
  • HY-10985
    Marizomib
    15+ Cited Publications

    Salinosporamide A; NPI-0052

    		 Proteasome Cancer
    Marizomib (Salinosporamide A) is a second-generation, irreversible, brain-penetrant, pan-proteasome inhibitor. Marizomib inhibits the CT-L (β5), CT-T-laspase-like (C-L, β1) and trypsin-like (T-L, β2) activities of the 20S proteasome (IC50=3.5, 28, and 430 nM, respectively) .
    Marizomib
  • HY-10452
    Ixazomib citrate
    5+ Cited Publications

    MLN9708

    		 Proteasome Autophagy Cancer
    Ixazomib citrate (MLN9708) is a selective, orally active, second-generation proteasome inhibitor. Ixazomib citrate can be used for the study of a broad range of human malignancies .
    Ixazomib citrate
  • HY-10454
    Delanzomib
    4 Publications Verification

    CEP-18770

    		 Proteasome NF-κB Apoptosis Cancer
    Delanzomib (CEP-18770) is a potent and orally active chymotrypsin-like activity of the proteasome inhibitor with an IC50 of 3.8 nM. Delanzomib inhibits NF-κB activity, induces cancer cell apoptotic, and has strong antiangiogenic and anti-cancer activities .
    Delanzomib
  • HY-W017227
    Alloxan hydrate
    1 Publications Verification

    		 Proteasome Metabolic Disease Cancer
    Alloxan hydrate is a diabetogenic agent to induce diabetes. Alloxan hydrate is a proteasome inhibitor. Alloxan causes diabetes in experimental animals through its ability to destroy the insulin-secreting B-cells of the pancreas .
    Alloxan hydrate
  • HY-12113
    Oprozomib
    3 Publications Verification

    ONX 0912; PR-047

    		 Proteasome Autophagy Apoptosis Cancer
    Oprozomib (PR-047) is an orally bioavailable and selective peptide epoxyketone proteasome inhibitor with IC50s of 36 and 82 nM for proteasome (β5) and immunoproteasome (LMP7), respectively. Oprozomib (ONX 0912) induces apoptosis in MM cells .
    Oprozomib
  • HY-108552
    MG-115
    1 Publications Verification

    		 Proteasome Apoptosis Cancer
    MG-115 is a potent and reversible proteasome inhibitor, with Kis of 21 nM and 35 nM for 20S and 26S proteasome, respectively. MG-115 specifically inhibit the chymotrypsin-like activity of the proteasome, induces p53-dependent apoptosis .
    MG-115
  • HY-108549
    clasto-Lactacystin β-lactone

    Omuralide; β-Clastolactacystin

    		 Proteasome Cancer
    Clasto-Lactacystin β-lactone, a natural active metabolite of lactacystin, which is a metabolite of Streptomyces, acts as an irreversible 20S proteasome inhibitor.
    clasto-Lactacystin β-lactone
  • HY-10227R
    Bortezomib (Standard)

    PS-341 (Standard); LDP-341 (Standard); NSC 681239 (Standard)

    		 Reference Standards Proteasome NF-κB Apoptosis Autophagy TREM receptor Cancer
    Bortezomib (Standard) is the analytical standard of Bortezomib. This product is intended for research and analytical applications. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM) . Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) .
    Bortezomib (Standard)
  • HY-131350
    LXE408

    		Proteasome Parasite Infection
    LXE408 is an orally active, non-competitive and kinetoplastid-selective proteasome inhibitor. LXE408 has an IC50 of 0.04 μM for L. donovani proteasome and an EC50 of 0.04 μM for L. donovani. LXE408 has a low propensity to cross the blood brain barrier. LXE408 has the potential for visceral leishmaniasis (VL) research .
    LXE408
  • HY-P11306
    Biotin-(Oaa)3-epoxomicin

    		Proteasome NF-κB Inflammation/Immunology
    Biotin-(Oaa)3-epoxomicin is a biotin-labeled form of Epoxomicin (HY-13821), prepared by conjugating Epoxomicin with biotin via three hydrophilic oxaacetyl amino acid (Oaa) linkers. Biotin-(Oaa)3-epoxomicin is primarily used in proteomic studies for the capture, identification and target validation of proteasome complexes, to determine the intracellular targets of epoxomicin. Epoxomicin acts as a proteasome inhibitor and NF-κB inhibitor, which effectively blocks inflammatory responses in mouse ear edema assays. It inhibits proteasome activity via covalent binding to catalytic subunits including LMP7, X, MECL1 and Z, with the strongest inhibitory effect on chymotrypsin-like activity, and does not interfere with non-proteasomal proteases such as trypsin and papain .
    Biotin-(Oaa)3-epoxomicin
  • HY-108551
    MG-262
    1 Publications Verification

    Z-Leu-Leu-LeuB(OH)2; ZL3B

    		 Proteasome VEGFR Apoptosis Reactive Oxygen Species (ROS) Cardiovascular Disease Inflammation/Immunology Cancer
    MG-262 (Z-Leu-Leu-LeuB(OH)2; ZL3B) is a reversible proteasome inhibitor. MG-262 down-regulates VEGF receptor Flt-1. MG-262 inhibits cell growth and induces apoptosis in malignant cells. MG-262 induces reactive oxygen species (ROS). MG-262 can be used for anti-cancer study .
    MG-262
  • HY-W001023
    5-Amino-8-hydroxyquinoline

    5A8HQ; 5AHQ

    		 Proteasome NF-κB Cancer
    5-Amino-8-hydroxyquinoline (5A8HQ; 5AHQ) is an orally active non-competitive 20S proteasome inhibitor. 5-Amino-8-hydroxyquinoline can inhibit NF-κB activity and induce cancer cells death and shows low cytotoxicity towards normal hematopoietic cells. 5-Amino-8-hydroxyquinoline can be used for the research of cancer, such as leukemia .
    5-Amino-8-hydroxyquinoline
  • HY-107412
    Proteasome inhibitor IX

    PS-IX; AM114

    		 Proteasome Cancer
    Proteasome inhibitor IX (PS-IX; AM114) is a Chalcone derivative and a chymotrypsin-like activity of the 20S proteasome inhibitor with an IC50 value of ~1 μM. Proteasome inhibitor IX exhibits HCT116 p53 +/+ cells growth inhibitory activity with an IC50 value of 1.49 μM. Proteasome inhibitor IX has potent anticancer activity .
    Proteasome inhibitor IX
  • HY-10227S
    Bortezomib-d8

    PS-341-d8; LDP-341-d8; NSC 681239-d8

    		 Isotope-Labeled Compounds Proteasome NF-κB Apoptosis Autophagy TREM receptor Cancer
    Bortezomib-d8 is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM) . Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) .
    Bortezomib-d8
  • HY-13067R
    Celastrol (Standard)

    Tripterine (Standard); Tripterin (Standard)

    		 Reference Standards Proteasome Autophagy Mitophagy Apoptosis Endogenous Metabolite Inflammation/Immunology Cancer
    Celastrol (Standard) is the analytical standard of Celastrol. This product is intended for research and analytical applications. Celastrol (Tripterine;Tripterin) is a proteasome inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.
    Celastrol (Standard)
  • HY-151252
    NIC-0102

    		Proteasome NOD-like Receptor (NLR) Inflammation/Immunology
    NIC-0102 is an orally active proteasome inhibitor (pIC50=7.55) that specifically inhibits NLRP3 inflammatory vesicle activation. NIC-0102 shows potent anti-inflammatory effects in a model of dextran sulfate sodium (DSS)-induced ulcerative colitis. NIC-0102 also inhibits production of pro-IL-1β .
    NIC-0102
  • HY-111844
    PROTAC RAR Degrader-1

    		PROTACs SNIPERs RAR/RXR Neurological Disease Metabolic Disease Cancer
    PROTAC RAR degrader-1 (Compound 9) is a potent and selective RAR PROTAC Degrader consisting of apoptotic protein inhibitors (IAPs) ligands. IAPs-based degraders are also known as SNIPERs. PROTAC RAR Degrader-1 reduces RARα levels in HT1080 cells in a concentration-dependent manner but is blocked by the proteasome inhibitor MG132 (HY-13259). PROTAC RAR Degrader-1 can be used in the study of nuclear receptor-related diseases. (Pink: RAR ligand 1 (HY-111843); Black: Linker (HY-140189); Blue: IAPs Ligand (HY-B0134)) .
    PROTAC RAR Degrader-1
  • HY-10455R
    Carfilzomib (Standard)

    PR-171 (Standard)

    		 Reference Standards Proteasome Autophagy Apoptosis Cancer
    Carfilzomib (Standard) is the analytical standard of Carfilzomib. This product is intended for research and analytical applications. Carfilzomib (PR-171) is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells.
    Carfilzomib (Standard)
  • HY-158412
    BT317

    		Proteasome Apoptosis Cancer
    BT317 is a blood-brain transmissible mitochondrial Lon peptidase I (LonP1) and CT-L proteasome inhibitor. BT317 can increase the production of reactive oxygen species (ROS) and induce apoptosis in astrocytoma cells. BT317 has antitumor activity .
    BT317
  • HY-P1259A
    PR-39 TFA

    		Proteasome Bacterial Inflammation/Immunology
    PR-39 TFA, a natural proline- and arginine-rich antibacterial peptide, is a noncompetitive, reversible and allosteric proteasome inhibitor. PR-39 TFAreversibly binds to the α7 subunit of the proteasome and blocks degradation of NF-κB inhibitor IκBα by the ubiquitin-proteasome pathway. PR-39 TFA stimulates angiogenesis, inhibits inflammatory responses and significant reduces myocardial infarct size in mice .
    PR-39 TFA
  • HY-P2483B
    Octaarginine acetate

    		Bacterial Proteasome Infection Inflammation/Immunology Cancer
    Octaarginine acetate is a cell-penetrating peptide and proteasome inhibitor. Octaarginine acetate exhibits mixed-type inhibition against 20S proteasome chymotrypsin-like, caspase-like, and trypsin-like activities, and inhibits 26S proteasome activity with decreased efficiency. Octaarginine acetate induces ubiquitin-conjugated protein accumulation, mediates HSPG-dependent cellular internalization via macropinocytosis, enhances liposomal cargo uptake and gene delivery. Octaarginine acetate can be used for the research of cervix carcinoma, collagen antibody-induced arthritis, and bacterial infections .
    Octaarginine acetate
  • HY-P2483
    Octaarginine

    		Proteasome Bacterial Infection Inflammation/Immunology Cancer
    Octaarginine is a cell-penetrating peptide and proteasome inhibitor. Octaarginine exhibits mixed-type inhibition against 20S proteasome chymotrypsin-like, caspase-like, and trypsin-like activities, and inhibits 26S proteasome activity with decreased efficiency. Octaarginine induces ubiquitin-conjugated protein accumulation, mediates HSPG-dependent cellular internalization via macropinocytosis, enhances liposomal cargo uptake and gene delivery. Octaarginine can be used for the research of cervix carcinoma, collagen antibody-induced arthritis, and bacterial infections .
    Octaarginine
  • HY-P1258
    PSI
    2 Publications Verification

    Proteasome Inhibitor 1; Z-Ile-Glu(OtBu)-Ala-Leu-CHO

    		 Proteasome Infection Cancer
    PSI (Proteasome Inhibitor 1) is a potent proteasome inhibitor. PSI inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI has the potential for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas .
    PSI
  • HY-10455S
    Carfilzomib-d8

    		Isotope-Labeled Compounds Proteasome Autophagy Apoptosis Cancer
    Carfilzomib-d8 is deuterium labeled Carfilzomib. Carfilzomib (PR-171) is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells.
    Carfilzomib-d8
  • HY-128903
    MC-Val-Cit-PAB-carfilzomib iodide

    		Drug-Linker Conjugates for ADC Cancer
    MC-Val-Cit-PAB-carfilzomib iodide is a agent-linker conjugate for ADC with potent antitumor activity by using carfilzomib (an irreversible proteasome inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
    MC-Val-Cit-PAB-carfilzomib iodide
  • HY-139181
    NR160

    		HDAC Cancer
    NR160 is a selective HDAC6 inhibitor with an IC50 value of 30 nM. NR160 shows low cytotoxicity against leukemia cell line. NR160 augments the apoptosis induction of Bortezomib (HY-10227) (proteasome inhibitor), Epirubicin (HY-13624) and Daunorubicin (HY-13062A) significantly .
    NR160
  • HY-144452
    Immunoproteasome inhibitor 1

    		Proteasome Cancer
    Immunoproteasome inhibitor 1 is a potent, reversible, time-independent immunoproteasome and proteasome inhibitor (Kis of 1.18, 0.27, 1.91 μM in β5c, β1i, β5i submits, respectively). Immunoproteasome inhibitor 1 can be used for the research of certain neoplastic diseases .
    Immunoproteasome inhibitor 1
  • HY-132991
    ML 2-14
    1 Publications Verification

    		 PROTACs Epigenetic Reader Domain Cancer
    ML 2-14 is a PROTAC targeting BRD4 with a C4 alkyl linker. ML 2-14 consists of the E3 ligase ligand EN219 (HY-115715) (bule part), the target protein ligand JQ-1 (HY-13030) (red part), and the PROTAC linker (balck part). ML 2-14 can effectively degrade BRD4 in 231MFP breast cancer cells, and this effect can be reversed by the proteasome inhibitor Bortezomib (HY-10227) and the E1 activase inhibitor TAK-243 (HY-100487) .
    ML 2-14
  • HY-125939
    Bortezomib-pinanediol

    		Proteasome Cancer
    Bortezomib-pinanediol is a proteasome inhibitor and a prodrug of Bortezomib (HY-10227). Bortezomib-pinanediol inhibits cell growth and can be used for study of multiple myeloma .
    Bortezomib-pinanediol
  • HY-119288
    BC-23

    NSC 45382

    		 Proteasome Cancer
    BC-23 (NSC 45382) is a proteasome inhibitor. BC-23 exhibits good inhibition of CT-L activity of the proteasome and is selective for malignant over normal cells .
    BC-23
  • HY-10227G
    Bortezomib

    PS-341; LDP-341; NSC 681239

    		 Proteasome NF-κB Apoptosis Autophagy TREM receptor Cancer
    Bortezomib (GMP) (PS-341 (GMP)) is Bortezomib (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM) . Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) .
    Bortezomib
  • HY-N16453
    (+)-Catechin 3-gallate

    		Proteasome Neurological Disease Cancer
    (+)-Catechin 3-gallate is an orally active polyphenolic compound that acts as a non-selective proteasome inhibitor. (+)-Catechin 3-gallate exerts antitumor effects by inducing apoptosis and suppressing inflammatory cytokines. (+)-Catechin 3-gallate is promising for research of cancers (e.g., breast, prostate) and neurodegenerative diseases (e.g., Alzheimer’s) .
    (+)-Catechin 3-gallate
  • HY-P1259
    PR-39

    		Proteasome Bacterial Inflammation/Immunology
    PR-39, a natural proline- and arginine-rich antibacterial peptide, is a noncompetitive, reversible and allosteric proteasome inhibitor. PR-39 reversibly binds to the α7 subunit of the proteasome and blocks degradation of NF-κB inhibitor IκBα by the ubiquitin-proteasome pathway. PR-39 stimulates angiogenesis, inhibits inflammatory responses and significant reduces myocardial infarct size in mice .
    PR-39
  • HY-P10714
    Ub4ix

    		Proteasome Apoptosis Deubiquitinase Cancer
    Ub4ix is a DUB/26S proteasome inhibitor. Ub4ix can protect K48-linked Ub chains from being chopped up by deubiquitinating enzymes (DUBs) and prevent the proteasomal degradation of Ub-tagged proteins. Ub4ix can reduce the viability of Hela cells and induce apoptosis, with an IC50 value of 1.6 μM .
    Ub4ix
  • HY-W048404
    Bortezomib impurity A

    		Proteasome Cancer
    Bortezomib impurity A is a metabolite of the 20S proteasome inhibitor Bortezomib (HY-10227).
    Bortezomib impurity A
  • HY-120035
    DD1

    		Proteasome Ribosomal S6 Kinase (RSK) Apoptosis Cancer
    DD1, a proteasome inhibitor, targets Bax activation and P70S6K degradation during acute myeloid leukemia (AML) apoptosis. DD1 induces apoptosis in the caspase-dependent manner. DD1 induces mitochondrial membrane depolarization and Bad dephosphorylation .
    DD1
  • HY-10453R
    Ixazomib (Standard)

    MLN2238 (Standard)

    		 Reference Standards Proteasome Autophagy Cancer
    Ixazomib (Standard) is the analytical standard of Ixazomib. This product is intended for research and analytical applications. Ixazomib (MLN2238) is a selective, potent, and reversible proteasome inhibitor, which inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with an IC50 of 3.4 nM (Ki of 0.93 nM).
    Ixazomib (Standard)
  • HY-P4910
    Baceridin

    		Proteasome Apoptosis Cancer
    Baceridin is a proteasome inhibitor and a cyclic hexapeptide. Baceridin can be isolated from the culture medium of Epiphytic Bacillus. Baceridin can inhibit cell cycle progression and induce tumor cell apoptosis through a p53-independent pathway. Baceridin can be used in cancer research .
    Baceridin
  • HY-170881
    TIR-199

    		Proteasome Cancer
    TIR-199 is a novel and highly specific dual proteasome inhibitor that can effectively inhibit the PSMB5 subunit of constitutive proteasome and the PSMB8 subunit of immunoproteasome. TIR-199 can induce the death of various tumor cells. TIR-199 can be used for research on myeloma .
    TIR-199
  • HY-171956
    Carmaphycin-17

    		Proteasome Parasite Infection
    Carmaphycin-17 (CP-17) is a selective 20S proteasome inhibitor with an EC50 of 217 ?nM. Carmaphycin-17 has potent antimicrobial activity against Trichomonas vaginalis. Carmaphycin-17 overcomes Metronidazole (HY-B0318) resistance and significantly reduces parasite burden upon topical treatment without any apparent adverse effects in vaginal trichomonad infection mice model. Carmaphycin-17 can be used for sexually transmitted disease like trichomoniasis research .
    Carmaphycin-17
  • HY-13067G
    Celastrol

    Tripterine; Tripterin

    		 Endogenous Metabolite Proteasome Antibiotic Apoptosis Bacterial Autophagy Mitophagy Infection Inflammation/Immunology Cancer
    Celastrol (GMP) (Tripterine (GMP)) is Celastrol (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Celastrol (Tripterine;Tripterin) is a proteasome inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. In addition, Celastrol is also an antibiotic with potent antimicrobial activity against standard and clinical methicillin-resistant Staphylococcus aureus (MRSA) strains, inducing oxidative stress and inhibiting DNA synthesis by binding to P5CDH .
    Celastrol
  • HY-118522
    TP-110

    		Proteasome NF-κB Caspase PARP IAP Apoptosis Cancer
    TP-110 is a proteasome inhibitor. TP-110 specifically inhibits the protease-like activity of the 20S proteasome, but does not affect the trypsin-like or peptidyl-glutamyl peptide hydrolysis activity. TP-110 inhibits the NF-κB pathway, activates caspase-8, -9, and -3, and causes PARP cleavage, significantly reducing the levels of cIAP-1 and XIAP. TP-110 causes cell cycle arrest at the G2/M phase and promotes apoptosis of cancer cells. TP-110 can be used in cancer research of prostate cancer and multiple myeloma, etc .
    TP-110
  • HY-P1258A
    PSI TFA

    Proteasome Inhibitor 1 TFA; Z-Ile-Glu(OtBu)-Ala-Leu-CHO TFA

    		 Proteasome Infection Cancer
    PSI (TFA) is a potent proteasome inhibitor. PSI (TFA) inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI (TFA) can be used for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas .
    PSI TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: